Watch for full ESID 2026 presentation and Q4 2026 CVID Phase II topline results, which will determine registrational path for broader CVID indication.
Price Chart
Executive Summary
Pharming announced positive topline Phase II data for leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation, showing a mean 26.4% spleen volume reduction and a favorable safety profile. The results support expansion beyond the approved APDS indication, with topline CVID-specific Phase II results expected in Q4 2026.
Key Facts
- Phase II trial of leniolisib in 13 subjects with genetically defined PIDs showed mean 26.4% spleen volume reduction and reductions in index lesion size.
- Safety profile consistent with known leniolisib data; no new safety signals identified.
- 9 of 13 enrolled patients also had CVID; topline Phase II results for leniolisib in CVID expected in Q4 2026.
- Abstract accepted at ESID 2026 (October 14-17, Netherlands).
- Leniolisib is already approved for APDS in multiple regions including U.S., EU, Japan, and others.
Financial Impact
Positive data supports potential label expansion to broader PID population, significantly increasing addressable patient base beyond APDS. No financial figures provided.
Risk Factors
- Phase II trial is single-arm, open-label with small sample size (n=13); results may not replicate in larger controlled studies.
- CVID-specific Phase II results still pending; expansion into broader PID population is not guaranteed.
- Regulatory approval for new indications requires additional clinical data and regulatory review.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3365943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Press Release | — | awaiting T+20 | — | — |
Aug 13, 2026 10w ago | Press Release | — | awaiting T+20 | — | — |
Jul 30, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | — | awaiting T+20 | — | — |
May 28, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 7, 2026 29w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers